21 February 2024
21 February 2024
Following a review of the trial data, Oramed discovered that the oral insulin candidate was effective in a particular subset of patients.
Teva Pharmaceuticals and Sanofi signed a $1.5bn deal to co-develop the anti-TL1A therapy for inflammatory bowel disease in November 2023.
Polpharma’s biosimilar candidate PB106 showed non-inferiority to the reference therapy, Takeda’s Entyvo, in a Phase III trial.
The trial will assess the safety, immunogenicity, efficacy, and biomarker-based selection of NPX887 for various solid tumours.
The investigator-initiated, randomised, double-blind, placebo-controlled trial is anticipated to begin in mid-2024.
Roche will carry out and sponsor the randomised, international Phase Ib/II trial, which is part of its Morpheus-Liver programme.
The decision follows a serious adverse event of liver failure in a patient participating in the atopic dermatitis trial.
Tharimmune is planning to advance TH104 into a Phase II clinical trial later this year, funded by an $11m public offering from 2023.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
